MS drug Lemtrada does not benefit patients, FDA panel says

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

MS drug Lemtrada does not benefit patients, FDA panel says

Postby MSUK » Thu Nov 14, 2013 1:22 am

Lemtrada hasn’t proven to help against disability in the treatment of relapsing multiple sclerosis, said U.S. advisers who questioned whether the company’s studies were conducted well enough to assess the drug.

While the U.S. Food and Drug Administration advisory panel decided that potential safety risks don’t preclude approval of Lemtrada, its members voted 14-2 that the drug didn’t help improve a patient’s disability. The agency isn’t required to accept the recommendations of its advisers..... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2210
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Campath (Lemtrada, Alemtuzumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service